Search | Clinical Trials Finder

Conditions: Prostate Cancer
Interventions: Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score); Device · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 8
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 4 more

Conditions: Sars-CoV-2 Infection, COVID-19
Interventions: BinaxNOW Test, "Lollipop" swab; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 4 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults, AML (Adult) With 11q23 (MLL) Abnormalities, AML (Adult) With Del (5q), AML (Adult) With Inv (16) (p13; q22), AML (Adult) With t (16;16) (p13; q22), AML (Adult) With t (8; 21) (q22; q22), Secondary AML (Adult), Untreated AML (Adult)
Interventions: Decitabine, Midostaurin; Drug
Lead sponsor: David Iberri; Other
Eligibility: 60 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lung Cancer
Interventions: bevacizumab, Tecemotide, carboplatin, cyclophosphamide, paclitaxel, radiotherapy; Biological · Drug · Radiation
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 88
States / cities: Palo Alto, California • Stanford, California • Macon, Georgia + 61 more

Conditions: Glioblastoma, MGMT-Unmethylated Glioblastoma
Interventions: Microtubule-Targeted Agent BAL101553, Radiation Therapy; Drug · Radiation
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: rHSC-DIPGVax, Balstilimab, Zalifrelimab; Biological · Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Months to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Orange, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Schizophrenia
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Los Alamitos, California • Riverside, California • Hollywood, Florida + 3 more

Conditions: Recurrent Malignant Thymoma, Thymoma
Interventions: Diaphragm Fluoroscopy, Magnetic Resonance Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia
Interventions: Not listed
Lead sponsor: KineMed; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: San Diego, California • Rochester, Minnesota • New Hyde Park, New York + 2 more

Conditions: Multiple Myeloma
Interventions: BMS-986453; Drug
Lead sponsor: Susan Bal; Other
Eligibility: 19 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Development Delay, Neurodevelopmental Disorders, Autism
Interventions: Parents Taking Action; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Freeman-Burian Syndrome, Freeman-Sheldon Syndrome, Whistling Face Syndrome, Sheldon-Hall Syndrome, Freeman-Sheldon Syndrome Variant, Arthrogryposis Distal Type 1, Arthrogryposis Distal Type 3, Gordon Syndrome
Interventions: Guided Health History for Freeman-Burian Syndrome Questionnaire, Freeman-Burian syndrome Semi-Structured Quality of Life Interview, Medical Records Review, PTSD Checklist for DSM-5, Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale, Review of Systems, FACE-Q | Craniofacial - Appearance of the Face, FACE-Q | Craniofacial - Appearance Distress, FACE-Q | Craniofacial - Facial Function; Other
Lead sponsor: Dufresne, Craig, MD, PC; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: Innovis LLC; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Celebration, Florida • Baltimore, Maryland • Nashville, Tennessee

Conditions: Medulloblastoma
Interventions: Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention; Procedure · Drug · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 59 Months
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 10
States / cities: Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atrial Fibrillation
Interventions: Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later; Device
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 34,244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Coronary Artery Disease
Interventions: Regadenoson; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Neoplasms
Interventions: Contrast Enhanced Digital Mammography; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions: DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF; Biological · Drug
Lead sponsor: David Avigan; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight
Interventions: Electronic tool set for counseling overweight patients; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: 3D mammograpgy system; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Peripheral Vascular Disease, Cardiovascular Disease
Interventions: Vessel Closure (StarClose™); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 11
States / cities: La Jolla, California • Atlanta, Georgia • Peoria, Illinois + 8 more

Conditions: Cannabinoid Hyperemesis Syndrome
Interventions: Haloperidol; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Hodgkin's Lymphoma
Interventions: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Safe and Healthy Schools

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma

Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

Translating Peer-to-Peer Support Into a Clinical Setting

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome

A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

Phase Analysis and Obstructive CAD on Rubidium PET

Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Electronic Tools to Assist With Identification of and Counseling for Overweight Patients

A Comparison of the 15 and 30 Acquisition Angle Breast Tomosynthesis Mammography for Breast Abnormalities

RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System

Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas